PL1851206T3 - Rozuwastatyna i jej wolne od alkilenowych eterów sole oraz sposób ich wytwarzania - Google Patents

Rozuwastatyna i jej wolne od alkilenowych eterów sole oraz sposób ich wytwarzania

Info

Publication number: PL1851206T3
Authority: PL; Poland
Prior art keywords: rosuvastatin; alkylether; salts; preparation; free
Prior art date: 2005-02-22

Application number

PL06735971T

Other languages

English (en)

Inventor

Valerie Niddam-Hildesheim

Anna Balanov

Natalia Shenkar

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-22

Filing date

2006-02-22

Publication date

2013-01-31

2006-02-22 Application filed by Teva Pharma filed Critical Teva Pharma

2013-01-31 Publication of PL1851206T3 publication Critical patent/PL1851206T3/pl

Links

229960000672 rosuvastatin Drugs 0.000 title 2
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title 1
-1 rosuvastatin alkylether Chemical class 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1896—Compounds having one or more Si-O-acyl linkages
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL06735971T 2005-02-22 2006-02-22 Rozuwastatyna i jej wolne od alkilenowych eterów sole oraz sposób ich wytwarzania PL1851206T3 (pl)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
US65558005P	2005-02-22	2005-02-22
US67638805P	2005-04-28	2005-04-28
US72349105P	2005-10-03	2005-10-03
US72387505P	2005-10-04	2005-10-04
US73297905P	2005-11-02	2005-11-02
US75107905P	2005-12-15	2005-12-15
US76050606P	2006-01-19	2006-01-19
US76234806P	2006-01-25	2006-01-25
EP06735971A EP1851206B1 (en)	2005-02-22	2006-02-22	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
PCT/US2006/006519 WO2006091770A2 (en)	2005-02-22	2006-02-22	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof

Publications (1)

Publication Number	Publication Date
PL1851206T3 true PL1851206T3 (pl)	2013-01-31

Family

ID=38832611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06735971T PL1851206T3 (pl)	2005-02-22	2006-02-22	Rozuwastatyna i jej wolne od alkilenowych eterów sole oraz sposób ich wytwarzania

Country Status (11)

Country	Link
US (3)	US7612203B2 (pl)
EP (2)	EP1851206B1 (pl)
JP (2)	JP4713574B2 (pl)
KR (2)	KR101020024B1 (pl)
CA (4)	CA2594017C (pl)
ES (1)	ES2389565T3 (pl)
IL (2)	IL184035A (pl)
MX (1)	MX2007010138A (pl)
PL (1)	PL1851206T3 (pl)
TW (2)	TWI345562B (pl)
WO (2)	WO2006091770A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2546701C (en)	2003-11-24	2010-07-27	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
US7851624B2 (en) *	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) *	2003-12-24	2007-08-02	Valerie Niddam-Hildesheim	Process for preparation of statins with high syn to anti ratio
US7612203B2 (en)	2005-02-22	2009-11-03	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
EP1948618A1 (en) *	2006-09-18	2008-07-30	Teva Pharmaceutical Industries Ltd.	Crystalline rosuvastatin calcium
US8318933B2 (en) *	2006-10-31	2012-11-27	Aurobindo Pharma Ltd	Process for preparing rosuvastatin calcium
WO2008096257A1 (en) *	2007-02-08	2008-08-14	Aurobindo Pharma Limited	An improved process for preparation of rosuvastatin calcium
EP2062903A1 (en) *	2007-04-18	2009-05-27	Teva Pharmaceutical Industries Ltd.	Statin intermediates and process for the preparation of statins
JP2010501643A (ja)	2007-07-12	2010-01-21	テバファーマシューティカルインダストリーズリミティド	薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製
EA201000214A1 (ru)	2007-08-28	2010-10-29	Рациофарм Гмбх	Способ получения производных пентадикарбоновой кислоты
EP2298745B1 (en) *	2008-05-27	2014-09-03	Changzhou Pharmaceutical Factory	Preparation method of rosuvastatin calcium and its intermediates
CN101735272B (zh) *	2009-12-11	2012-10-31	重庆博腾制药科技股份有限公司	瑞舒伐他汀钙中间体的制备方法
CN102212082B (zh) *	2010-04-05	2015-03-04	重庆博腾制药科技股份有限公司	瑞舒伐他汀钙中间体及制备方法
US20110313131A1 (en) *	2010-06-21	2011-12-22	Christelle Carl	Reversed phase hplc purification of a glp-1 analogue
RS60310B1 (sr)	2010-08-10	2020-07-31	Rempex Pharmaceuticals Inc	Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
HU230987B1 (hu) *	2010-11-29	2019-08-28	Egis Gyógyszergyár Nyrt.	Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
US9012491B2 (en)	2011-08-31	2015-04-21	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
KR20150103270A (ko)	2013-01-04	2015-09-09	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko)	2013-01-04	2015-09-09	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
JP6114475B2 (ja)	2013-07-16	2017-04-12	スヴェン・ライフ・サイエンシズ・リミテッド	ロスバスタチンカルシウムを製造するための方法及びその新規な中間体の製造方法
SI3140310T1 (sl)	2014-05-05	2020-01-31	Rempex Pharmaceuticals, Inc.	Sinteza boronatnih soli in njihova uporaba
EP3139930B1 (en)	2014-05-05	2024-08-14	Melinta Therapeutics, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2015179308A1 (en)	2014-05-19	2015-11-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru)	2014-07-01	2017-06-30	Ремпекс Фармасьютикалз, Инк.	Производные бороновой кислоты и их терапевтическое применение
WO2016081297A1 (en)	2014-11-18	2016-05-26	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en)	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
KR101710976B1 (ko) *	2015-04-08	2017-02-28	임광민	키랄 화합물의 제조방법 및 이를 이용한 HMG-CoA 환원저해제의 제조방법
KR20160126700A (ko)	2015-04-24	2016-11-02	미래파인켐 주식회사	스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
ES2894251T3 (es)	2016-06-30	2022-02-14	Qpex Biopharma Inc	Derivados de ácido borónico y usos terapéuticos de los mismos
MX2020003495A (es)	2017-10-11	2020-09-18	Qpex Biopharma Inc	Derivados de acido boronico y sintesis de los mismos.
US12016868B2 (en)	2018-04-20	2024-06-25	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
CN108845058A (zh) *	2018-08-13	2018-11-20	江苏悦兴医药技术有限公司	一种瑞舒伐他汀钙起始物料的高效液相色谱检测方法
BR112022022367A2 (pt)	2020-05-05	2023-01-10	Qpex Biopharma Inc	Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
CN115677768A (zh) *	2022-09-27	2023-02-03	宿迁阿尔法科技有限公司	一种(3r)-叔丁基二甲硅氧基-5-氧代-6-三苯基膦烯己酸甲酯的合成方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en)	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
NO177005C (no)	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5189164A (en) *	1989-05-22	1993-02-23	Sandoz Ltd.	Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
JPH03223231A (ja) *	1990-01-29	1991-10-02	Daiso Co Ltd	蓚酸モノエステル誘導体の製造法
US5177080A (en)	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5202029A (en)	1991-03-13	1993-04-13	Caron Kabushiki Kaisha	Process for purification of hmg-coa reductase inhibitors
JP3233403B2 (ja)	1991-06-19	2001-11-26	塩野義製薬株式会社	光学活性な中間体および該製造法
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
GB9211796D0 (en) *	1992-06-04	1992-07-15	Ici Plc	Heterocyclic derivatives
US5218138A (en) *	1992-09-02	1993-06-08	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
JPH06107599A (ja) *	1992-09-30	1994-04-19	Taoka Chem Co Ltd	芳香族ジカルボン酸モノエステル類の製造方法
JP3400038B2 (ja)	1993-10-19	2003-04-28	塩野義製薬株式会社	ピリミジン誘導体の製造方法
US5741934A (en) *	1996-04-10	1998-04-21	Sandler; Stanley R.	Preparation of primary mercaptans
GB9626746D0 (en)	1996-12-23	1997-02-12	Knoll Ag	Process
GB9812413D0 (en)	1998-06-10	1998-08-05	Glaxo Group Ltd	Compound and its use
DE19841342A1 (de) *	1998-09-10	2000-04-20	Merck Patent Gmbh	Neue Reaktivsysteme aus polymerisierbaren Monomeren , die Peroxide und stabilisierten Boralkylverbindungen enthalten
SI20070A (sl)	1998-09-18	2000-04-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0028429D0 (en)	2000-11-22	2001-01-10	Astrazeneca Ab	Therapy
AU2002324715B2 (en)	2001-08-16	2009-03-12	Teva Pharmaceutical Industries Ltd.	Processes for preparing calcium salt forms of statins
KR20040026705A (ko)	2001-08-16	2004-03-31	테바 파마슈티컬 인더스트리즈 리미티드	스타틴의 칼슘 염 형태의 제조 방법
SE0103509D0 (sv)	2001-10-19	2001-10-19	Astrazeneca Ab	Rosuvastatin in pre demented states
KR100511533B1 (ko) *	2002-04-09	2005-08-31	임광민	키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EA200401533A1 (ru)	2002-05-21	2005-06-30	Ранбакси Лабораторис Лимитед	Способ получения росувастатина
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
DK1578733T3 (da)	2002-12-10	2011-06-14	Ranbaxy Lab Ltd	Fremgangsmåde til fremstilling af rosuvastatin
WO2004103977A2 (en) *	2003-05-21	2004-12-02	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) *	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
WO2005021511A1 (en)	2003-08-27	2005-03-10	Hetero Drugs Limited	A novel process for amorphous rosuvastatin calcium
EP1816126A1 (en)	2003-08-28	2007-08-08	Teva Pharmaceutical Industries Limited	Process for preparation of rosuvastatin calcium
CA2537271A1 (en)	2003-08-28	2005-03-17	Teva Pharmaceutical Industries, Ltd.	Process for preparation of rosuvastatin calcium
EP1678148A1 (en)	2003-10-22	2006-07-12	Ranbaxy Laboratories Limited	Process for the preparation of amorphous rosuvastatin calcium
CA2546701C (en)	2003-11-24	2010-07-27	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
WO2005077916A1 (en)	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Salts of hmg-coa reductase inhibitors and use thereof
CN1894221B (zh) *	2003-12-02	2012-08-08	特瓦制药工业有限公司	用于表征罗苏伐他汀的参照标准品
CA2550742A1 (en)	2003-12-24	2005-07-14	Teva Pharmaceutical Industries Ltd.	Process for preparation of statins with high syn to anti ratio
US20070179166A1 (en)	2003-12-24	2007-08-02	Valerie Niddam-Hildesheim	Process for preparation of statins with high syn to anti ratio
EP1797046A2 (en)	2004-09-27	2007-06-20	Ranbaxy Laboratories Limited	Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
WO2006079611A1 (en)	2005-01-31	2006-08-03	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of rosuvastatin calcium salt
US7612203B2 (en)	2005-02-22	2009-11-03	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en)	2005-02-22	2007-02-15	Valerie Niddam-Hildesheim	Preparation of rosuvastatin
WO2006100689A1 (en)	2005-03-22	2006-09-28	Unichem Laboratories Limited	Process for preparation of rosuvastatin
WO2006106526A1 (en)	2005-04-04	2006-10-12	Unichem Laboratories Limited	Process for preparation of calcium salt of rosuvastatin
CN1872841A (zh)	2005-06-01	2006-12-06	信谊药厂	瑞舒伐他汀钙及其关键中间体的制备方法
CA2612587C (en)	2005-06-24	2013-02-19	Lek Pharmaceuticals D.D.	Process for preparing amorphous rosuvastatin calcium free of impurities
WO2006136408A2 (en)	2005-06-24	2006-12-28	Lek Pharmaceuticals D.D.	Process for preparing pure amorphous rosuvastatin calcium
GB0514078D0 (en)	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
WO2007099561A1 (en)	2006-02-27	2007-09-07	Cadila Healthcare Limited	Process for preparing rosuvastatin calcium

2006
- 2006-02-22 US US11/360,289 patent/US7612203B2/en not_active Expired - Fee Related
- 2006-02-22 JP JP2007509753A patent/JP4713574B2/ja not_active Expired - Fee Related
- 2006-02-22 CA CA2594017A patent/CA2594017C/en not_active Expired - Fee Related
- 2006-02-22 WO PCT/US2006/006519 patent/WO2006091770A2/en not_active Ceased
- 2006-02-22 EP EP06735971A patent/EP1851206B1/en not_active Expired - Lifetime
- 2006-02-22 CA CA2591439A patent/CA2591439C/en not_active Expired - Fee Related
- 2006-02-22 CA CA002680693A patent/CA2680693A1/en not_active Abandoned
- 2006-02-22 MX MX2007010138A patent/MX2007010138A/es not_active Application Discontinuation
- 2006-02-22 WO PCT/US2006/006520 patent/WO2006091771A2/en not_active Ceased
- 2006-02-22 EP EP06735972A patent/EP1737829A2/en not_active Withdrawn
- 2006-02-22 JP JP2007549737A patent/JP2008526781A/ja active Pending
- 2006-02-22 TW TW095106000A patent/TWI345562B/zh not_active IP Right Cessation
- 2006-02-22 ES ES06735971T patent/ES2389565T3/es not_active Expired - Lifetime
- 2006-02-22 KR KR1020077018633A patent/KR101020024B1/ko not_active Expired - Fee Related
- 2006-02-22 KR KR1020077018312A patent/KR100945763B1/ko not_active Expired - Fee Related
- 2006-02-22 TW TW095105998A patent/TWI353981B/zh not_active IP Right Cessation
- 2006-02-22 PL PL06735971T patent/PL1851206T3/pl unknown
- 2006-02-22 CA CA002683975A patent/CA2683975A1/en not_active Abandoned
- 2006-09-12 US US11/520,296 patent/US7582759B2/en not_active Expired - Fee Related
2007
- 2007-06-19 IL IL184035A patent/IL184035A/en not_active IP Right Cessation
- 2007-06-19 IL IL184036A patent/IL184036A0/en unknown
2009
- 2009-03-11 US US12/381,449 patent/US8063211B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2006091771A3 (en)	2007-01-11
WO2006091771A2 (en)	2006-08-31
US20060258882A1 (en)	2006-11-16
WO2006091770A2 (en)	2006-08-31
TW200640878A (en)	2006-12-01
EP1851206A2 (en)	2007-11-07
US8063211B2 (en)	2011-11-22
JP2008526781A (ja)	2008-07-24
ES2389565T3 (es)	2012-10-29
KR20070100970A (ko)	2007-10-15
TW200724533A (en)	2007-07-01
US20090209567A1 (en)	2009-08-20
TWI353981B (en)	2011-12-11
JP4713574B2 (ja)	2011-06-29
TWI345562B (en)	2011-07-21
KR100945763B1 (ko)	2010-03-08
CA2591439A1 (en)	2006-08-31
IL184036A0 (en)	2007-10-31
IL184035A0 (en)	2007-10-31
US20070191436A1 (en)	2007-08-16
EP1737829A2 (en)	2007-01-03
WO2006091770A3 (en)	2007-05-31
MX2007010138A (es)	2007-09-27
EP1851206B1 (en)	2012-08-15
IL184035A (en)	2012-10-31
JP2007533764A (ja)	2007-11-22
KR101020024B1 (ko)	2011-03-09
CA2594017A1 (en)	2006-08-31
CA2594017C (en)	2010-04-20
KR20070095414A (ko)	2007-09-28
WO2006091771A8 (en)	2007-04-19
US7612203B2 (en)	2009-11-03
US7582759B2 (en)	2009-09-01
CA2591439C (en)	2013-03-26
CA2680693A1 (en)	2006-08-31
CA2683975A1 (en)	2006-08-31

Publication	Publication Date	Title
IL184035A0 (en)	2007-10-31	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
IL192241A (en)	2014-01-30	A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
ZA200804198B (en)	2009-04-29	Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
ZA200903533B (en)	2010-03-31	Process for the preparation of rosuvastatin
EP2035410A4 (en)	2010-11-03	PROCESS FOR PREPARING ESOMEPRAZOLE AND ITS SALTS
PL1737850T3 (pl)	2008-02-29	Nowy sposób wytwarzania linezolidu i związków pokrewnych
IL189781A0 (en)	2008-08-07	Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
IL183528A0 (en)	2007-09-20	Process for preparing rosuvastatin
SI2086945T1 (sl)	2016-05-31	Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
ZA200708811B (en)	2009-01-28	Use of a sulfonamide compound for improving the pharma-cokinetics of a drug
IL212639A0 (en)	2011-07-31	Piperazine salt and a process for the preparation thereof
ZA200801854B (en)	2009-08-26	Method of preparing esomeprazole and salts thereof
IL184787A0 (en)	2007-12-03	Oral dosage form comprising rosiglitazone
PL1856038T3 (pl)	2012-04-30	Sposób wytwarzania zawierającego mocznik strumienia wodnego
ZA200804264B (en)	2009-01-28	Process for the preparation of ferri-succinylcasein
TWI346402B (en)	2011-08-01	Method for the production of a luminesence-diode chip and luminesence-diode chip
IL184790A0 (en)	2007-12-03	Oral dosage form comprising rosiglitazone
ZA200803152B (en)	2009-06-24	Oramucosal pharmaceutical dosage form
IL190325A0 (en)	2009-09-22	A process for the preparation of halofenate
GB0513984D0 (en)	2005-08-17	Dosage form
PL1763508T3 (pl)	2011-12-30	Sposób wytwarzania mocznika
ZA200601910B (en)	2006-11-29	Process for the preparation of organosilances
PL1700855T3 (pl)	2015-09-30	Sposób wytwarzania tazarotenu
IL187948A0 (en)	2008-03-20	Preparation of rosuvastatin
ZA200803761B (en)	2009-09-30	Process for the preparation of a leukotriene antagonist and intermediates thereof